anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Two research assistants will conduct the study. Experimenter A assists with recruitment of subjects, sets up the test environment and performs the trunk release. Experimenter B acts as the primary data collector and will be kept blind to the purpose of the study.

The randomized allocation indicates if the subject is in the intervention or control group. Experimenter A sets up the study hospital bed fitted with a visco-elastic foam mattress, a fitted sheet, a flat sheet and the torso pressure-sensing mat. For standardization, the mat is aligned with markers set on the bed frame. Subjects will wear hospital pajamas over undergarments. Experimenter B records height, weight, age and gender. Subject is seated in a chair and is instructed in the spirometry maneuver. Once the subject is comfortable with the maneuver, Experimenter A asks the subject to lie supine with their body centered on the bed and with their hands resting on their abdomen. Experimenter A reminds the subject to remain completely immobile for the duration of data collection. Experimenter B takes a baseline measure of discomfort as per protocol. Experimenter A places the subject in the High Fowler's position by raising the foot of the bed to its highest position, 50 degrees, and the head of the bed to its highest position, 60 degrees. Experimenter A sets the timer for 8 minutes as per pressure mapping protocol. For more stable values, a "settling time" of 8 minutes is required to factor in creep of the pressure mapping sensors and mattress. Experimenter A aims the laser beam to the top of the scapulae where the subject's shoulder meets the mattress surface. Experimenter B initiates a FSA file with the subject's number, takes a pressure reading once 8 minutes is up, measures the trunk displacement, obtains spirometry readings as per protocol, and takes a measure of discomfort. Experimenter B leaves the room, Experimenter A sets the timer for 5 minutes and opens the allocation envelope.

The Principal Investigator will conduct random spot checks to ensure consistency in set-up.
1,199,186. Cephaloglycin. ELI LILLY & CO. 24 Oct., 1967 [24 Oct., 1966], No. 48244/67. Heading C2A. The invention relates to a pure, stable crystalline form of 7-(D-α-aminophenylacetamido) cephalosporanic acid, which is substantially non-hygroscopic, contains less than 1% by wt. of water and has the following X-ray diffraction data: The compound is prepared by dissolving or slurrying hydrated cephaloglycin in M-methylformamide or formamide or a mixture thereof under substantially anhydrous conditions, commingling the resulting solution or slurry with a substantially water-free antisolvent for cephaloglycin which is C 1-4  alcohol, acetonitrile, propionitrile, butanonitrile or a C 1-7  alkyl alkanoate to effect a precipitation of cephaloglycin crystals and drying the resulting crystals to obtain crystals which contain less than 1% by weight of water. It is preferred to use a slurry of cephaloglycin in a mixture of formamide and methanol, the formamide being present in a ratio of at least 1À25 ml. per gram of cephaloglycin and the methanol being present in an amount to maintain the viscosity of the mixture as a stirrable solid-containing liquid medium. Specification 985,747 is referred to. A pharmaceutical composition comprises the aforesaid cephaloglycin and a carrier.
Children ages 6 to 18 years will be available for participation in this multicenter study. Subjects will be enrolled from community based general pediatric clinics and other well-child care areas within participating hospitals and clinics of the four participating sites. Enrollment will continue until a total of 85 subjects from each age category (6-\<12 years and ≥12- \<18 years) successfully complete the study.
Sham manual lymph drainage; deep pressure was applied from distal to proximal with rapid movements to the right extremity to which the cold pressure test was applied. Fingers, dorsal and palmar surfaces of the hand, forearm, elbow, and upper arm were applied in order. The application was performed while the patient was lying in the supine position and lasted an average of 20 minutes.
PURPOSE:To obtain a skin external preparation capable of preventing injury of skin cells by ultraviolet ray and having a preventive effect on aging of skin by blending water-extracted material of mammalian spleen with amino acid (derivative). CONSTITUTION:A mammalian spleen e.g. fresh frozen spleen of cattle is pulverized and extracted with >=60 deg.C hot water for >=1hr and further heated at >=80 deg.C for >=10min and filtered and concentrated. Ethyl alcohol is added to the concentrate to remove protein and further the mixture is filtered to clarify the mixture. Then the clarified solution is subjected to an ultrafiltration using a capillary membrane filtration system having 2000 separation limit molecular weight to provide water-extracted material of spleen. 0.0001-5.0wt.% (as dried solid content) of the water-extracted material and 0.005-5.0wt.% of one or more substance selected from amino acid and amino acid derivative are mixed into total amount of skin external preparation.
Allergic Reactions: Allergic and anaphylactoid reactions associated with lidocaine or prilocaine can occur. They are characterized by urticaria, angioedema, bronchospasm, and shock. If they occur they should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value. 

Systemic (Dose Related) Reactions: Systemic adverse reactions following appropriate use of lidocaine and prilocaine cream are unlikely due to the small dose absorbed (see Pharmacokinetics subsection of CLINICAL PHARMACOLOGY). Systemic adverse effects of lidocaine and/or prilocaine are similar in nature to those observed with other amide local anesthetic agents including CNS excitation and/or depression (light-headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest). Excitatory CNS reactions may be brief or not occur at all, in which case the first manifestation may be drowsiness merging into unconsciousness. Cardiovascular manifestations may include bradycardia, hypotension and cardiovascular collapse leading to arrest.
The usual initial antihypertensive oral dose of Amlodipine besylate tablets is 5 mg once daily, and the maximum dose is 10 mg once daily.

Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding Amlodipine besylate tablets to other antihypertensive therapy.

Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps. Titrate more rapidly, however, if clinically warranted, provided the patient is assessed frequently.

Angina:The recommended dose for chronic stable or vasospastic angina is 5 to 10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg for adequate effect. 

Coronary artery disease:The recommended dose range for patients with coronary artery disease is 5 to 10 mg once daily. In clinical studies, the majority of patients required 10 mg [see Clinical Studies (14.4)] .
A material having the following five characteristics simultaneously and thereby has significantly delayed recrystallization has been created for the first time. The first characteristic is that the type of a surfactant which is used must be a surfactant having at least two tails. The second characteristic is that the size of an insoluble material to which the surfactant is adhered is desirably between 1-10μm. The third characteristic is that the size of the insoluble material to which the surfactant is adhered is extremely homogenous. The fourth characteristic requires that the material, according to the present invention, is not standardized as much as possible, unlike liposomes according to existing techniques. The fifth characteristic is that a form dissolved in water is intended to be in an emulsified form. The present invention relates to the method for manufacturing the material as above.
The invention discloses a traditional Chinese medicine preparation for treating radioactive cerebral type encephalomyelopathy. The radioactive cerebral type encephalomyelopathy is caused by temporal lobe injuries by external irradiation in the traditional Chinese medicine, and has symptoms of reoccurring headaches, dizziness, sleepiness and memory deterioration. Syndrome differentiation in traditional Chinese medicine is kidney deficiency and essence depletion, and malnutrition of brain. The traditional Chinese medicine preparation is prepared by selecting the following traditional Chinese medicines with the effects of reinforcing kidney to replenish essence, improving brain and inducing resuscitation, namely triplostegia glandulifera, oriental waterplantain fruits, cauda cervi, boxthorn leaf, thinleaf adina fruit, medical angiopteris rhizome, root of shrubberry rhodiola, many-nerved bauhinia leaf, fruit of chinese holly and mint. According to the clinical test in the hospital, the traditional Chinese medicine preparation is remarkable in curative effect, and has the total effective rate of 94.7% which is obviously higher than that of a control group. Moreover, the traditional Chinese medicine preparation is free of toxic and side effect, low in treatment cost and worthy of clinical popularization and application.
BACKGROUND: The quantification of mRNA expression in urinary sediments is a reliable biomarker for various diseases. However, few studies have investigated the clinical relevance of urinary mRNA levels in IgA nephropathy (IgAN). Thus, we investigated the expression of urinary mRNAs and their clinical significance in IgAN.
METHODS: Overall, 200 patients with biopsy-proven IgAN, 48 disease controls, and 76 healthy controls were enrolled. We identified the differential expression of mRNAs in renal tissue between patients with IgAN and normal subjects using the Gene Expression Omnibus dataset and selected candidate mRNAs. mRNA expression in the urinary sediment was measured using quantitative real-time polymerase chain reaction. Associations between urinary mRNA levels and clinicopathological parameters were analyzed and the predictive value of mRNAs for disease progression was evaluated.
RESULTS: The urinary expression of CCL2, CD14, DNMT1, FKBP5, Nephrin, and IL-6 was significantly upregulated in patients with IgAN compared with healthy controls. C3, FLOT1, and Podocin levels were significantly correlated with renal function, where C3, FLOT1, and TfR levels were significantly correlated with urinary protein excretion. During follow-up, 26 (13.0%) patients with IgAN experienced disease progression, defined as a greater than 50% reduction in the estimated glomerular filtration rate or progression to end-stage renal disease. Urinary mRNA levels of FLOT1 (HR 3.706, 95% CI 1.373-10.005, P = 0.010) were independently associated with an increased risk of disease progression.
CONCLUSIONS: Our results suggest that urinary sediment mRNAs are a useful biomarker in IgAN patients. Further studies with larger sample sizes and longer follow-up durations are required.
BACKGROUND: Childhood obesity and overweight are associated with musculoskeletal pain, but the association between low back pain (LBP) and overweight/obesity in this population needs clarification. The objective of this meta-analysis is to ascertain the relationship between LBP and obesity/overweight in children and adolescents.
METHODS: Various databases and specialized journals were queried from inception to October 2022. Encompassed were all studies examining the association between overweight or obesity and LBP among participants aged 6 to 18 years. The ROBINS-E tool was employed to assess bias. Random-effects models were used to pool results across studies, with location-scale models used to search for moderator variables where evidence of heterogeneity was found.
RESULTS: In total, 34 studies were incorporated. Four studies had a low risk of bias, while the remaining studies had some concerns. Nine studies evinced an association between overweight and LBP, in contrast to normal weight, yielding an OR of 1.13 (95% CI 1.10-1.16) and no heterogeneity. Eight studies demonstrated a similar association between obesity and LBP compared to normal weight, with an OR of 1.27 (95% CI 1.20-1.34) and no heterogeneity. Ten studies established an association between overweight/obesity and LBP compared to normal weight, yielding an OR of 1.18 (95% CI 1.14-1.23) and no heterogeneity. Finally, nineteen studies showcased an association between body mass index (BMI) and LBP, with an OR of 1.19 (95% CI 1.03-1.39) with evidence of heterogeneity. For this last analysis, we compared the mean BMI in groups and transformed results to log OR, and then retransformed to OR.
CONCLUSION: Overweight and obesity may be risk factors for LBP in children and adolescents. The association between LBP and obesity appears to be stronger than with overweight. However, the analysis revealed considerable heterogeneity and risk of bias across studies.
OBJECTIVE: To conduct an environmental scan and appraisal of online patient resources to support rheumatoid arthritis (RA) flare self-management.
METHODS: We used the Google search engine (last search March 2023) using the terms "rheumatoid arthritis" and "flare management." Additional searches targeted major arthritis organizations, as well as regional, national, and international resources. Appraisal of the resources was conducted by 2 research team members and 1 patient partner to assess the understandability and actionability of the resource using the Patient Education Materials Assessment Tool (PEMAT). Resources rating ≥ 60% in both domains by either the research team or the patient partner were further considered for content review. During content review, resources were excluded if they contained product advertisements, inaccurate information, or use of noninclusive language. If content review criteria were met, resources were designated as "highly recommended" if both patient partners and researchers' PEMAT ratings were ≥ 60%. If PEMAT ratings were divergent and had a rating ≥ 60% from only 1 group of reviewers, the resource was designated "acceptable."
RESULTS: We identified 44 resources; 12 were excluded as they did not pass the PEMAT assessment. Fourteen resources received ratings ≥ 60% on understandability and actionability from both researchers and patient partners; 10 of these were retained following content review as "highly recommended" flare resources. Of the 18 divergent PEMAT ratings, 8 resources were retained as "acceptable" following content review.
CONCLUSION: There is high variability in the actionability and understandability of online RA flare materials; only 23% of resources were highly recommended by researchers and patient partners.
The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics. It will be supplied in lyophilized form in each sachet containing 1 g of placebo, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
<P>PROBLEM TO BE SOLVED: To provide a new medicinal composition for administration to mucosa and having low osmotic pressure.  <P>SOLUTION: The medicinal composition for administration to mucosa and for application to pharmacotherapy comprises a water-insoluble and/or slightly water-soluble material and an aqueous medium and has less than 290 mOsm osmotic pressure. The composition has superior transitivity in blood to conventional medicinal compositions for administration to musca. And a composition for administration to mucosa, comprising a hemostatic agent and a medicament, is provided. The composition has superior osmosis and retention in the mucosal tissue to the conventional medicinal compositions.  <P>COPYRIGHT: (C)2004,JPO
Antimicrobial fabrics having a topically applied silver-based antimicrobial finish are provided. The finish comprises at least one silver ion-containing compound and at least one binder compound. The antimicrobial fabric may be formed into a garment to be worn as a base layer garment, close to the skin, which aids in the prevention of skin infection caused by abrasions to the skin. The garment may also aid in preventing the transfer of microbes from one person to another, for instance, after sharing communal items such as protective athletic equipment. The antimicrobial fabric exhibits long lasting antimicrobial efficacy against both Gram positive and Gram negative microbes and also exhibits antimicrobial efficacy after repeated wash cycles. Also provided is a method for making the silver-containing antimicrobial fabric.
INTRODUCTION: Deep vein thrombosis (DVT) is a medical condition characterized by forming a blood clot, or thrombus, in one of the deep veins, typically in the legs. It is a type of venous thromboembolism, which refers to the formation of blood clots in the veins. It is caused by Virchow's triad (stasis, hypercoagulation, and endothelial injury).
OBJECTIVE: Our main objective is to explore the effectiveness and safety of rivaroxaban and edoxaban in treating lower extremity DVT.
METHODS: We conducted a retrospective study involving 406 patients subjected to DVT treatment using direct oral anticoagulants (edoxaban and rivaroxaban) at our hospital. We recruited adult patients (aged 18 years and more) diagnosed with lower extremity DVT and received treatment with either rivaroxaban or edoxaban as the primary anticoagulant therapy for DVT. We excluded patients who received treatment with other anticoagulant medications (warfarin and heparin) as the primary therapy for DVT.
RESULTS: The groups showed statistically significant differences in red blood cell count and hemoglobin levels, with the edoxaban group having high values. However, the 2 groups observed no statistically significant differences in creatinine clearance, white blood cell count, platelet count, C-reactive protein, and D-dimer levels. The difference in the incidence of pulmonary embolism between the 2 groups was statistically significant (P value < 0.001). The edoxaban group had fewer pulmonary embolism patients than the rivaroxaban group. The reduction in recurrent thrombosis was significantly higher in the rivaroxaban group compared to the edoxaban group. There were no significant differences in the major bleeding at various sites across the 2 treatment groups (P > 0.05).
CONCLUSIONS: Rivaroxaban's pharmacokinetic profile includes rapid absorption and a relatively short half-life. It means that once administered, rivaroxaban quickly reaches its peak concentration in the blood and is subsequently eliminated from the body within a relatively short period. Edoxaban's pharmacokinetic profile may include slower absorption and a longer half-life than rivaroxaban. It can result in a slower rate of achieving peak concentration and a more prolonged presence in the bloodstream. These results emphasize the need for careful consideration of anticoagulant therapy in patients with underlying cancer and underscore the importance of managing risks while providing adequate anticoagulation to prevent thrombotic events.
FIELD: cosmetology. SUBSTANCE: invention deals with a composition base capable for preparation of cosmetic composition containing at least one silicon fluid and at least one gel-forming agent which includes siloxane groups and groups capable of forming hydrogen bonds for thickening of compositions. Said composition is a nonvolatile hard substance at room temperature dissolved in liquid including silicon at temperature of 25-250 C with forming a translucent or transparent solution at said temperature. The invention deals with a cosmetic composition having antiperspirant for diminishing unpleasant odor of a man, and also with method for diminishing unpleasant odor of a man. EFFECT: higher efficiency. 65 cl, 5 dwg, 3 tbl
The rotator cuff is a group of four muscles around the shoulder. They function to provide both shoulder mobility and power as well as stability. Rotator cuff tears can be a significant cause of pain and disability for the patient. Surgical repair is done to reconnect the torn tendon(s) to the bone and has been shown to be an effective treatment in the presence of full-thickness tears. The goals of Rotator Cuff (RC)surgery are to decrease pain, increase range of motion(ROM) and strength. This is done with a small incision called a mini-open. Standard care following this surgical repair is to be placed in a sling for 6 weeks to protect the repaired shoulder tendons. During this time ROM exercises are done using the non-operated arm for assistance. No active or voluntary movement is allowed during the first 6 weeks. Unfortunately, some of these patients develop shoulder stiffness which slows their recovery and return to work or daily activities and may result in increased use and cost of rehabilitation services.

The purpose of this study is to determine if following a RC repair, patients can safely stop wearing their sling and begin active ROM for activities of daily living as early as pain and comfort allow. A total of 190 patients have been recruited to this study (95/group) were randomly assigned to one of two study groups. Patients in Group A (sling for 6 weeks) will wear their sling for 6 weeks. Self-assisted ROM exercises are allowed at any time, but active movement will not be allowed until 6 weeks after surgery. Patients in Group B (Sling as needed) will be allowed to remove their sling as early as pain and comfort allow. Self-assisted ROM exercises are allowed at any time as are active ROM for activities of daily living. Patients who agree to participate will be seen by their surgeon and the research coordinator for a baseline assessment before surgery and again at 2 \& 6 weeks, 3, 6, 12 and 24 months after surgery. Each visit will include a ROM assessment and disease specific quality of life questionnaires. Patients will also undergo an Ultrasound exam at a minimum of 2 years after surgery to verify the integrity of their RC repair. Differences in ROM, questionnaire scores, RC integrity and adverse events will be examined between the two groups.
Embodiments of the disclosure provide systems and methods for generating a diagnosis report based on a medical image of a patient. The system includes a communication interface configured to receive the medical image acquired by an image acquisition device. The system further includes at least one processor. The at least one processor is configured to detect a medical condition of the patient and parameters associated with the medical condition based on the medical image. The at least one processor is further configured to construct the diagnosis report based on the medical image, wherein the diagnosis report includes at least one view of the medical image and a description of the medical condition using the parameters. The system also includes a display configured to display the diagnosis report.
FIELD: medicine; surgery. SUBSTANCE: method involves infiltration anesthesia of the abdominal wall with Novocain solution after preparation of the surgery area. The cyst is punctured with a thick needle under echographic control, and a syringe is used to evacuate the cyst contents. The cyst space is filed with some sclerosing solution (one quarter of the evacuated volume), the solution id evacuated after an exposure period of 5-8 min, and the cyst space is washed with physiological salt solution. The remaining space is filled with gel-like biomaterial (one half of evacuated liquid volume) before withdrawing the needle. The method allows the liver tissue to regenerate owing to proliferation of hepatocytes. EFFECT: prevention of complications and post-puncture relapse.